95% CI, 0.73-0.87), with no increase in risk for severe hypoglycemia, retinopathy or pancreatic adverse effects
Many frameworks step up by 50 mcg every one to two weeks toward a 200 mcg daily maintenance level
Another potential issue is that beneficiaries who participate in the short-term program will need to be enrolled in a Part D plan that participates in the longer-term demonstration, called the BALANCE Model, to continue accessing Medicare coverage of GLP-1s for obesity starting in 2027
[email protected] www.linkedin.com/in/christina-badaracco/ To subscribe to the SOULFUL Insights health and wellness newsletter click here.
Others, like melanotan-2, carry documented risks including mole changes and nausea
To keep things relatively simple, I have used dosages for semaglutide only